Bullstory Research August 3, 2026
Hytech Pharm(106190) 11year financial data, check this before investing
Key takeaways
Hytech Pharm(106190) 2026year 1quarter operating profit turned to a loss at -11won, after the provision for valuation loss on work-in-process inventory of 491,407thousand won was fully reversed, showing that the process yield had normalized. Rather than the apparent loss, more weight should be placed on the signal of production resumption.
If you searched for Hitechpharm (106190.KQ), there is one thing you want to know: what this company’s financial condition is really like, and where that evidence came from.
To start with, Hitechpharm is a KOSDAQ-listed stock, and 2015from 2025to 11years of financial data have been verified based on disclosures filed in OpenDART (the Financial Supervisory Service’s electronic disclosure system). In this article, we look at how to read that data and what remains unfilled.
Start by checking the listing information
Investment judgment begins with separating confirmed facts from projections that have not yet been confirmed. Hitechpharm’s listing information and market data were verified at a certain time, and the stock identification information (verifiedIdentity) was confirmed true. That means stock code 2026matches the actual Hitechpharm entity.831017106190
So far, this is the baseline. What really matters is the financial flow.
Do not view years of financials as a single year11.
Hytec Pharm’s financial data was2015 years from2025 years through11 years, verified from OpenDART disclosure materials as the source. The verification time was2026year8month3day at10a.m.17and10a.m., so the financial history was rechecked a little later than the listing information.57minute
11The period of years is important. If you judge based on only one year’s performance, it is easy to be fooled by temporary factors such as expense recognition, asset sales, or an industry cycle. Looking across multiple years shows whether sales and profit are steadily increasing or whether they spiked only in a particular year.
The problem is that this article itself does not list specific sales and operating profit figures. What has been verified is the fact that "11years of data exist and the source has been confirmed"; whether those figures are good or bad is a separate matter. You have to open the numbers yourself.
How should this data actually be used?
Summarized as a checklist, it is as follows.
- Look at the verification time first. If you do not know when the data was confirmed, you cannot tell whether it is current.
- Compare the overall trend over 11 years rather than a single year. Do not look only at 2015 and 2025; you need to examine the intervening years as well to see the direction.
- Forecasts, dividends, and earnings announcements are separate items. Even if the financial history has been verified, that does not mean future outlooks have been verified as well. You should separately confirm whether each item’s verification time is still valid now.
- Exclude items that still have no basis from your judgment. Filling blank parts with assumptions is not investment judgment; it is speculation.
What someone searching for Hite Pharm really needs to know is not just a stock code. It is which data about this stock has actually been verified, and which parts are still empty. What has been confirmed so far is listing information and 11years of financial source data. The rest should be left unjudged until the evidence is filled in.
Frequently asked questions
Hytech Pharm 2026year 1quarter core performance numbers only — which items should investors be sure to look at?
The key figures are sales of 141million won and operating profit of -11million won. There is no net income figure in the body, so investors should focus on operating profit and inventory changes.
Explain Hitec Pharm’s business structure in terms of revenue mix — which products generate earnings?
The key point is that the carbapenem line accounts for 86.4% of sales. The combined share of ertapenem and imipenem is 93.2%, indicating a high degree of product concentration.
What does the change in inventories mean? Please summarize it in numbers.
The key point is an increase in inventories at book value of +4,322,097thousand won, for a total of 48,049,515thousand won. This is interpreted as a signal of validation and shipment waiting ahead of commercial production.
2025After a blank in IR communication since the year 9month, what does holding an earnings presentation on 6month 24day mean?
The key point is that it is holding an earnings presentation about 2025years, 9months after the year 9months later on 6month 24day. This reflects that external communication was limited by pre-shipment validation and NDA.
Please summarize future momentum and risks in numeric terms — what are the key figures such as order concentration and sales-channel dependence?
The key momentum is exports 100% and ACS Dobfar channel dependence 87.4%. The risks are concentration in high-priced carbapenem sales and short-term production gaps due to validation.